ArticleThe Laryngoscope2026
Postoperative Effects of Celecoxib on Opioid Use and Pain Control After Benign Oropharyngeal Surgery.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo establish how celecoxib use after tonsillectomy and adenoidectomy (T&A) and modified uvulopalatopharyngoplasty (UPPP) affect pain scores and opioid consumption.
methodsPatients undergoing T&A or UPPP with tonsillectomy (May-October 2024) completed surveys on postoperative days (POD) 0, 1, 5, and 10 to assess pain scores and opioid use. All patients received a multimodal pain regimen, and cohorts were based on the prescription of celecoxib. The noncelecoxib cohort was a historical control group obtained via study data from Butkus et al. (December 2020-January 2023). Wilcoxon rank-sum and chi-squared tests were performed using R Studio.
resultsEighty patients were included (mean 33.0 years [SD = 12]), 66% female; 34% male; 55% Caucasian. The celecoxib cohort (N = 38) consumed an average of 66.2 mL (SD = 62.1) of opioids, and the non-celecoxib cohort (N = 42) received an average of 118.4 mL (SD = 91.6) (p = 0.021). There were no significant differences in pain scores reported on POD 1, 5, or 10 (p = 0.5, p = 0.2, p = 0.6, respectively).
conclusionThe addition of postoperative celecoxib resulted in a significant decrease in mean opioid consumption. Our data also demonstrate that postoperative pain was controlled similarly based on patient reported pain scores, regardless of celecoxib consumption. Further investigation is warranted with larger sample sizes to determine the efficacy of postoperative celecoxib use. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.